Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.52 |
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14122884 | 0.84 | IMPDH2 (0.44) | SRCEGFRERBB2MAP2K1GAK | |
| SCHEMBL19957128 | 0.83 | MET (0.52) | SRCEGFRERBB2PDGFRBPDGFRA | |
| SCHEMBL4400367 | 0.80 | PDGFRB (0.72) | SRCEGFRPDGFRBPDGFRA | |
| SCHEMBL14217352 | 0.80 | EGFR (0.45) | SRCEGFRERBB2MAP2K1 | |
| SCHEMBL23069237 | 0.79 | HTR1A (0.54) | SRCEGFRMAP2K1GAK | |
| SCHEMBL31297311 | 0.79 | KDM4E (0.55) | SRCEGFRMAP2K1GAK | |
| SCHEMBL26841078 | 0.79 | KDM4E (0.55) | SRCEGFRMAP2K1GAK | |
| SCHEMBL17136805 | 0.78 | SRC (0.50) | SRCEGFRERBB2 | |
| SCHEMBL30497323 | 0.78 | SRC (0.50) | SRCEGFRERBB2 | |
| SCHEMBL24009286 | 0.78 | MAP2K1 (0.46) | SRCEGFRERBB2PDGFRBMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338455-B2 | Pyridines or pyrimidines having 4-(hydrogenated 1-pyridyl- or hydrogenated 1-isoquinolyl rings, e.g., N-(4-chlorophenyl)-2-(pyridin-4-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-5-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer | AMGEN INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2118088-B1 | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer | AMGEN INC (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2118088-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING INFLAMMATION, ANGIOGENESIS AND CANCER | Amgen Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161346-A1 | Compounds and methods of use | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008079292-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079292-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN TREATING INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161346-A1 | Compounds and methods of use | VHL, VEGFA, FLT1 | SRC 1238/4885EGFR 381/4885ERBB2 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.